LGVN - Longeveron Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Miami,
United States
Type: Equity
LGVN price evolution
LGVN
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.22 | $0.18 | $0.11 | $0.1 |
| Inventory | ||||
| Total current assets | $13.41 | $3.76 | $5.85 | $5.04 |
| Long term investments | ||||
| Property, plant & equipment | $3.43 | $3.49 | $3.75 | $3.85 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $19.39 | $9.7 | $12.08 | $11.63 |
| Current liabilities | ||||
| Accounts payable | $0.6 | $1.47 | $0.64 | $0.83 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3.21 | $5.29 | $3.89 | $3.39 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4.48 | $6.66 | $5.34 | $4.99 |
| Shareholders' equity | ||||
| Retained earnings | -$100.96 | -$89.04 | -$84.98 | -$78.96 |
| Other shareholder equity | -$0 | $0 | -$0.1 | -$0.41 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.82 | |||
| Short term investments | ||||
| Net receivables | $0.11 | $0.22 | $0.06 | $0.42 |
| Inventory | ||||
| Total current assets | $5.85 | $20.28 | $35.38 | $1.85 |
| Long term investments | ||||
| Property, plant & equipment | $3.75 | $4.48 | $4.88 | $3.6 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $7.39 | |||
| Total investments | ||||
| Total assets | $12.08 | $27.41 | $42.77 | $9.24 |
| Current liabilities | ||||
| Accounts payable | $0.64 | $1.75 | $0.65 | $1.59 |
| Deferred revenue | $0.01 | |||
| Short long term debt | ||||
| Total current liabilities | $3.89 | $4.87 | $2.71 | $3.83 |
| Long term debt | $0.31 | |||
| Total noncurrent liabilities | $3.45 | |||
| Total debt | ||||
| Total liabilities | $5.34 | $6.91 | $5.31 | $7.28 |
| Shareholders' equity | ||||
| Retained earnings | -$84.98 | -$62.77 | -$43.94 | |
| Other shareholder equity | -$0.1 | -$0.46 | -$0.1 | $1.96 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.47 | $0.37 | ||
| Cost of revenue | ||||
| Gross Profit | $0.16 | $0.3 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $4.38 | $3.69 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.1 | -$0.1 | ||
| Net income | ||||
| Net income | -$5.62 | -$3.51 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.31 | $5.63 | $5.64 | $2.13 |
| Cost of revenue | ||||
| Gross Profit | $0.59 | $1.83 | $1.75 | $0.68 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $18.04 | $6.41 | $5.64 | $7.05 |
| Operating income | -$3.78 | -$3 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.01 | $0 | $0.02 | |
| Net income | ||||
| Net income | -$17.05 | -$3.72 | -$2.96 | -$6.34 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.11 | $2.28 | $0.77 | -$10.7 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.32 | -$0.29 | -$0.14 | $45.17 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$12.08 | -$5.43 | -$3.52 | $24.83 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | 30 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | -$3.72 | -$2.96 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$2.36 | -$2.39 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$10.7 | -$0.26 | -$0.13 | -$0.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $45.17 | $1.58 | $0.35 | $1.36 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $24.83 | -$1.05 | -$2.17 | -$4.03 |
News
Fundamentals
| Market cap | $18.82M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 9.60M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.18 |
| Quick ratio | N/A |